BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32780918)

  • 1. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
    Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.
    Ha H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Res Treat; 2019 Apr; 51(2):832-840. PubMed ID: 30309223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
    Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.
    Park W; Bang JH; Nam AR; Jin MH; Seo H; Kim JM; Oh KS; Kim TY; Oh DY
    Cancer Res Treat; 2021 Jan; 53(1):199-206. PubMed ID: 33070562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
    Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK; Azad NS; Lesinski GB
    Clin Cancer Res; 2022 Oct; 28(19):4336-4345. PubMed ID: 35833954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer.
    Garajová I; Cavazzoni A; Verze M; Minari R; Pedrazzi G; Balsano R; Gelsomino F; Valle RD; Digiacomo G; Giovannetti E; Leonardi F
    Life (Basel); 2022 Jun; 12(7):. PubMed ID: 35888050
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis.
    Lei C; Peng X; Gong X; Fan Y; Wu S; Liu N; Li L; Huang J; Zheng G; Long Z
    Aging (Albany NY); 2019 Dec; 11(24):12568-12580. PubMed ID: 31881008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
    Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
    Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer.
    Jo J; Kwon HW; Park S; Oh DY; Cheon GJ; Bang YJ
    J Nucl Med; 2017 Aug; 58(8):1255-1261. PubMed ID: 28254865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
    Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
    Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.
    Quatromoni JG; Suzuki E; Okusanya O; Judy BF; Bhojnagarwala P; Venegas O; Eruslanov E; Predina JD; Albelda SM; Singhal S
    BMC Immunol; 2013 Jul; 14():30. PubMed ID: 23865808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
    Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
    J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
    PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.